GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Forward PE Ratio

Hansoh Pharmaceutical Group Co (HKSE:03692) Forward PE Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Forward PE Ratio?

Hansoh Pharmaceutical Group Co's Forward PE Ratio for today is 0.00.

Hansoh Pharmaceutical Group Co's PE Ratio without NRI for today is 30.42.

Hansoh Pharmaceutical Group Co's PE Ratio for today is 29.24.


Hansoh Pharmaceutical Group Co Forward PE Ratio Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Forward PE Ratio Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend
Forward PE Ratio

Hansoh Pharmaceutical Group Co Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Hansoh Pharmaceutical Group Co's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Forward PE Ratio falls into.



Hansoh Pharmaceutical Group Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Hansoh Pharmaceutical Group Co  (HKSE:03692) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Hansoh Pharmaceutical Group Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Executives
Cen Junda 2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited 2301 Trustee
Jqc Holding Limited 2201 Interest of corporation controlled by you
Jqc International Limited 2201 Interest of corporation controlled by you
Sun Yuan 2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited 2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd. 2101 Beneficial owner
Sunrise Investment Advisors Limited 2201 Interest of corporation controlled by you
Zhong Huijuan 2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd. 2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines